decitabine vs hydroxyurea for advanced proliferative cmml
Published 3 years ago • 789 plays • Length 3:55Download video MP4
Download video MP3
Similar videos
-
2:16
determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
-
0:59
hdxsim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in scd
-
1:40
challenges and options for patients with hydroxyurea-resistant pv
-
2:00
optimizing hma treatment in hr-mds: azacitidine versus decitabine
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
3:28
preclinical studies of tasquinimod in mds: in vitro and in vivo investigations
-
1:46:07
hematology lecture
-
4:48
the top 10 most promising medical technologies updated - the medical futurist
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
2:23
oral combination of astx727 (decitabine/cedazuridine) plus ven for older/unfit patients with aml
-
2:18
the all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with aml
-
0:58
adapt: evaluating the use of hydroxyurea to reduce transfusion in ugandan children with scd
-
3:35
onvansertib with cytarabine or decitabine for r/r aml
-
2:41
an overview of the latest advances in hematology
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:46
guadecitabine in higher-risk mds/cmml: a phase ii trial
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
1:54
risk-adapted therapy: three-day versus five-day oral decitabine in patients with mds